Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Return on Capital Employed of 95.88% for Q1 2026, down 5073.0% year-over-year from 1.93% in Q1 2025, and down 21.03% quarter-over-quarter from 79.22% in Q4 2025.
Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Return on Capital Employed for 16 consecutive years, with 95.88% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5073.0% year-over-year to 95.88%; the TTM figure through Mar 2026 stood at 95.88% (down 5073.0% YoY), while the FY2025 annual figure was 119.1%, down 3907.0% from the prior year.
- Return on Capital Employed declined to 95.88% in Q1 2026 per WHWK's latest filing, from 79.22% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 36.8% in Q4 2022 and bottomed at 110.71% in Q4 2024.
- Historically, Return on Capital Employed has averaged 69.23% across 5 years, with a median of 66.11% in 2025.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 12641 bps — and 2023, when it soared 6501 bps.
- Whitehawk Therapeutics' Return on Capital Employed stood at 36.8% in 2022, then sank by 78 bps to 65.6% in 2023, then tumbled by 69 bps to 110.71% in 2024, then increased by 28 bps to 79.22% in 2025, then decreased by 21 bps to 95.88% in 2026.
- Business Quant data shows WHWK's Return on Capital Employed at 95.88% in Q1 2026, 79.22% in Q4 2025, and 66.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | -57.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.55% |
| Mar 31, 2026 | -95.88% |
| Dec 31, 2025 | -79.22% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -45.15% |
| Dec 31, 2024 | -110.71% |
| Sep 30, 2024 | -85.07% |
| Jun 30, 2024 | -83.92% |
| Mar 31, 2024 | -73.25% |
| Dec 31, 2023 | -65.60% |
| Sep 30, 2023 | -55.79% |
| Jun 30, 2023 | -45.20% |
| Mar 31, 2023 | -41.14% |
| Dec 31, 2022 | -36.80% |
| Sep 30, 2022 | -44.02% |
| Jun 30, 2022 | -110.21% |
| Mar 31, 2022 | -87.26% |
| Dec 31, 2021 | -75.11% |
| Sep 30, 2021 | -94.91% |